Tags

Type your tag names separated by a space and hit enter

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
Int J Antimicrob Agents. 2020 May; 55(5):105967.IJ

Abstract

The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.

Authors+Show Affiliations

Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, 600117, Chennai, India. Electronic address: praveennandan.1993@gmail.com.Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, 600117, Chennai, India. Electronic address: ranadheer.pharmd@gmail.com.Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, India. Electronic address: hodpchemistry@velsuniv.ac.in.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32259575

Citation

Praveen, D, et al. "Janus Kinase Inhibitor Baricitinib Is Not an Ideal Option for Management of COVID-19." International Journal of Antimicrobial Agents, vol. 55, no. 5, 2020, p. 105967.
Praveen D, Puvvada RC, M VA. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents. 2020;55(5):105967.
Praveen, D., Puvvada, R. C., & M, V. A. (2020). Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. International Journal of Antimicrobial Agents, 55(5), 105967. https://doi.org/10.1016/j.ijantimicag.2020.105967
Praveen D, Puvvada RC, M VA. Janus Kinase Inhibitor Baricitinib Is Not an Ideal Option for Management of COVID-19. Int J Antimicrob Agents. 2020;55(5):105967. PubMed PMID: 32259575.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. AU - Praveen,D, AU - Puvvada,Ranadheer Chowdary, AU - M,Vijey Aanandhi, Y1 - 2020/04/04/ PY - 2020/03/18/received PY - 2020/03/20/revised PY - 2020/03/26/accepted PY - 2020/4/8/pubmed PY - 2020/5/29/medline PY - 2020/4/8/entrez KW - Baricitinib KW - COVID 19 KW - Novel Corona Virus KW - SARS-CoV-2 SP - 105967 EP - 105967 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 55 IS - 5 N2 - The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/32259575/Janus_kinase_inhibitor_baricitinib_is_not_an_ideal_option_for_management_of_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(20)30124-2 DB - PRIME DP - Unbound Medicine ER -